300347 泰格医药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-2.0434.2661.9439.97210.643
总资产报酬率 ROA (%)-1.4693.1141.3897.0897.840
投入资产回报率 ROIC (%)-1.7443.6611.6278.2779.110

边际利润分析
销售毛利率 (%)27.52527.41533.95438.57739.637
营业利润率 (%)-2.12114.77310.06233.68036.446
息税前利润/营业总收入 (%)-1.02316.14410.63932.23534.257
净利润/营业总收入 (%)-5.00311.7826.78229.11632.062

收益指标分析
经营活动净收益/利润总额(%)-447.13251.849149.45573.53474.609
价值变动净收益/利润总额(%)555.69947.455-50.42427.76524.701
营业外收支净额/利润总额(%)1.953-0.6180.0060.0640.115

偿债能力分析
流动比率 (X)2.4862.1791.7202.7412.978
速动比率 (X)2.4612.1641.7122.7352.972
资产负债率 (%)17.21414.46616.06717.61117.363
带息债务/全部投入资本 (%)14.4609.93113.09414.35313.711
股东权益/带息债务 (%)576.303879.094644.373578.707604.915
股东权益/负债合计 (%)405.638510.912448.724402.258410.935
利息保障倍数 (X)-0.89711.04218.455-21.973-15.350

营运能力分析
应收账款周转天数 (天)66.45172.85371.43355.78646.665
存货周转天数 (天)3.5882.6662.2851.8101.191